Chemotherapy-Induced Peripheral Neuropathy

Terri Armstrong

Lois Almadrones

Mark R. Gilbert

ONF 2007, 32(2), 305-311. DOI: 10.1188/05.ONF.305-311
Purpose/Objectives: To review the literature documenting the scope, treatment, and prevention of chemotherapy-induced neuropathy.

Jump to a section

    References

    Aghajanian, C., Soignet, S., Dizon, D.S., Pien, C.S., Adams, J., Elliott, P.J., et al. (2002). A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clinical Cancer Research, 8, 2505-2511.
    Almadrones, L., Armstrong, T., Gilbert, M., & Schwartz, R. (2002). Chemotherapy-induced neurotoxicity: Current trends in management. A multidisciplinary approach. Philadelphia: Phillips Group Oncology Communications.
    Almadrones, L.A., & Arcot, R. (1999). Patient guide to peripheral neuropathy. Oncology Nursing Forum, 26, 1359-1360.
    Aventis Pharmaceuticals. (2003). Taxotere® (docetaxel) injection [Package insert]. Bridgewater, NJ: Author.
    Barbano, R., Hart-Gouleau, S., Pennella-Vaughan, J., & Dworkin, R.H. (2003). Pharmacotherapy of painful diabetic neuropathy. Current Pain and Headache Reports, 7, 169-177.
    Bristol-Myers Squibb Company. (2000). Taxol® (paclitaxel) injection [Package insert]. New York: Author.
    Cassileth, B.R., Vickers, A., Seidler, A., & Miner, W. (2002). Significant reductions in fatigue, pain, nausea, anxiety and depression following massage therapy [Abstract 1471]. Proceedings of the American Society of Clinical Oncology, 21, 368a.
    Cavaletti, G., Marzorati, L., Bogliun, G., Colombo, N., Marzola, M., Pittelli, M.R., et al. (1992). Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer, 69, 203-207.
    Cavaletti, G., & Zanna, C. (2002). Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. European Journal of Cancer, 38, 1832-1837.
    Cersosimo, R.J. (1989). Cisplatin neurotoxicity. Cancer Treatment Reviews, 16, 195-211.
    Dyck, P.J., Dyck, P.J., Grant, I.A., & Fealey, R.D. (1996). Ten steps in characterizing and diagnosing patients with peripheral neuropathy. Neurology, 47, 10-17.
    Furlong, T.G. (1993). Neurologic complications of immunosuppressive cancer therapy. Oncology Nursing Forum, 20, 1337-1352.
    Gilbert, M.R. (2000). Neurologic complications. In M.D. Abeloff, J.O. Armitage, A.S. Lichter, & J.E. Neiderhuber (Eds.), Clinical oncology (2nd ed., pp. 89-105). New York: Churchill Livingstone.
    Haim, N., Barron, S.A., & Robinson, E. (1991). Muscle cramps associated with vincristine therapy. Acta Oncologica, 30, 707-711.
    Hay, J.W. (2002). Quality of life effects of chemotherapy-induced neuropathy in ovarian cancer [Abstract 886]. Proceedings of the American Society of Clinical Oncology, 21, 222a.
    Hilkens, P.H., Verweij, J., Stoter, G., Vecht, C.J., van Putten, W.L., & van den Bent, M.J. (1996). Peripheral neurotoxicity induced by docetaxel. Neurology, 46, 104-108.
    Hohneker, J.A. (1994). A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Seminars in Oncology, 21(Suppl. 10), 42-47.
    Holden, S., & Felde, G. (1987). Nursing care of patients experiencing cisplatin-related peripheral neuropathy. Oncology Nursing Forum, 14(1), 13-17.
    Holland, J.F., Scharlau, C., Gailani, S., Krant, M.J., Olson, K.B., Horton, J., et al. (1973). Vincristine treatment of advanced cancer: A cooperative study of 392 cases. Cancer Research, 33, 1258-1264.
    Jacobson, S.D., Loprinzi, C.L., Sloan, J.A., Wilke, J.L., Novotny, P.J., Okuno, S.H., et al. (2002). Glutamine for preventing paclitaxel-associated myalgias and arthralgias: Unfortunately a "no go" [Abstract 1460]. Proceedings of the American Society of Clinical Oncology, 21, 366a.
    Kaplan, E., Kleinman, M., Patel, A., Kozloff, M., Tangonan, C., Cowan, M., et al. (2001). Amifostine as a rescue agent in patients with chemotherapy-induced peripheral neuropathy [Abstract 2959]. Proceedings of the American Society of Clinical Oncology, 20, 302b.
    Kaplan, R.S., & Wiernik, P.H. (1982). Neurotoxicity of antineoplastic drugs. Seminars in Oncology, 9, 103-130.
    Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., et al. (1996). Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. Journal of Clinical Oncology, 14, 2101-2112.
    Legha, S.S. (1986). Vincristine neurotoxicity. Pathophysiology and management. Medical Toxicology, 1, 421-427.
    Lipton, R.B., Apfel, S.C., Dutcher, J.P., Rosenberg, R., Kaplan, J., & Berger, A. (1989). Taxol produces a predominantly sensory neuropathy. Neurology, 39, 368-373.
    Lorusso, D., Ferrandina, G., Greggi, S., Gadducci, A., Pignata, S., Tateo, S., et al. (2003). Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology, 14, 1086-1093.
    Pazdur, R., Kudelka, A.P., Kavanagh, J.J., Cohen, P.R., & Raber, M.N. (1993). The taxoids: Paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treatment Reviews, 19, 351-386.
    Pollera, C.F., Pietrangeli, A., & Giannarelli, D. (1991). Cisplatin-induced peripheral neurotoxicity: Relationship to dose intensity. Annals of Oncology, 2, 212.
    Quasthoff, S., & Hartung, H.P. (2002). Chemotherapy-induced peripheral neuropathy. Journal of Neurology, 249, 9-17.
    Rambaud, L., Freyer, G., Taieb, S., Guilloton, L., Descos, L., Gaget, R., et al. (2001). Managing oxaliplatin (OXA) neurosensory toxicity: The use of somesthetic evoked potentials (SEP) is no more discriminating than a rigorous clinical follow-up [Abstract 1627]. Proceedings of the American Society of Clinical Oncology, 20, 408a.
    Rapoport, B.L., Vorobiof, D.A., Chasen, M.R., McMichael, G., Cohen, G., Eek, R., et al. (2002). Low incidence of neurotoxicity in patients (pts) undergoing chemotherapy with docetaxel and carboplatin (CBDCA): Results of a phase II first line study in advanced ovarian cancer [Abstract 862]. Proceedings of the American Society of Clinical Oncology, 21, 216a.
    Richardson, P. (2003). Clinical update: Proteasome inhibitors in hematologic malignancies. Cancer Treatment Reviews, 29(Suppl. 1), 33-39.
    Roca, E., Bruera, E., Politi, P.M., Barugel, M., Cedaro, L., Carraro, S., et al. (1985). Vinca alkaloid-induced cardiovascular autonomic neuropathy. Cancer Treatment Reports, 69, 149-151.
    Roelofs, R.I., Hrushesky, W., Rogin, J., & Rosenberg, L. (1984). Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology, 34, 934-938.
    Rosenthal, S., & Kaufman, S. (1974). Vincristine neurotoxicity. Annals of Internal Medicine, 80, 733-787.
    Rowinsky, E.K., Chaudhry, V., Forastiere, A.A., Sartorius, S.E., Ettinger, D.S., Grochow, L.B., et al. (1993). Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. Journal of Clinical Oncology, 11, 2010-2020.
    Rowinsky, E.K., Eisenhauer, E.A., Chaudhry, V., Arbuck, S.G., & Donehower, R.C. (1993). Clinical toxicities encountered with paclitaxel (Taxol). Seminars in Oncology, 20(4, Suppl. 3), 1-15.
    Schaible, H., & Richter, F. (2004). Pathophysiology of pain. Current Concepts in Clinical Surgery. Retrieved May 4,2004, from http://springerlink.metapress.com
    Teravainen, H., & Larsen, A. (1977). Some features of the neuromuscular complications of pulmonary carcinoma. Annals of Neurology, 2, 495-502.
    Thompson, S.W., Davis, L.E., Kornfeld, M., Hilgers, R.D., & Standefer, J.C. (1984). Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer, 54, 1269-1275.
    Vahdat, L., Papadopoulos, K., Lange, D., Leuin, S., Kaufman, E., Donovan, D., et al. (2001). Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clinical Cancer Research, 7, 1192-1197.
    van Gerven, J.M., Moll, J.W., van den Bent, M.J., Bontenbal, M., van der Burg, M.E., Verweij, J., et al. (1994). Paclitaxel (Taxol) induces cumulative mild neurotoxicity. European Journal of Cancer, 30A, 1074-1077.
    Vasey, P.A. (2002). Survival and longer-term toxicity results of the SCOTROC study: Docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC) [Abstract 804]. Proceedings of the American Society of Clinical Oncology, 21, 202a.
    von Schlippe, M., Fowler, C.J., & Harland, S.J. (2001). Cisplatin neurotoxicity in the treatment of testicular germ cell tumour: Incidence, time course and prognosis [Abstract 776]. Proceedings of the American Society of Clinical Oncology, 20, 195a.
    Walsh, T.J., Clark, A.W., Parhad, I.M., & Green, W.R. (1982). Neurotoxic effects of cisplatin therapy. Archives of Neurology, 39, 719-720.
    Yalcin, S., Nurlu, G., Orhan, B., Zeybek, D., Muftuoglu, S., Sarer, B., et al. (2003). Protective effect of amifostine against cisplatin-induced motor neuropathy in rat. Medical Oncology, 20, 175-180.